Raymond James Financial
ALLO icon

Raymond James Financial’s Allogene Therapeutics ALLO Stock Holding History

Raymond James Financial’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-45
Closed -$51 – 5011
2025
Q2 		$51 Buy
+45
New +$60 ﹤0.01% 6884

Other funds holding ALLO

P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Raymond James Financial's ALLO Position: Q3 2025 in Review

Raymond James Financial sold out of Allogene Therapeutics (ALLO) in Q3 2025, closing a stake of 45 shares — an estimated $51 sold.

Raymond James Financial first reported a position in ALLO in Q2 2025 and held it in 1 quarter. The position peaked at $51 in Q2 2025. 170 funds tracked by Wall St. Rank hold ALLO as of Q3 2025.

  • Raymond James Financial reported no remaining Allogene Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Raymond James Financial sold 45 Allogene Therapeutics shares in Q3 2025, an estimated $51.
  • Raymond James Financial first reported a position in Allogene Therapeutics in Q2 2025 and held it in 1 quarter.
  • Raymond James Financial's Allogene Therapeutics position peaked at $51 in Q2 2025.
  • 170 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q3 2025.

Based on Raymond James Financial's 13F filing for Q3 2025, filed 14 Nov 2025.